Cysticercosis is a parasitic infectious disease characterized by cyst formation in the target tissue of Taenia solium (tapeworm) parasite larvae ingested via the feces of a human with a tapeworm (huma...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation surrounding cysticercosis is limited due to its relatively low prevalence and the challenges in conducting systematic clinical studies. As a parasitic infection, it may not receive the same level of research attention as genetic disorders. Additionally, the variability in clinical presentation and the lack of identified genetic factors contribute to the gaps in understanding this condition.
Cysticercosis primarily affects the nervous system, with key clinical features including seizures (30-79% prevalence), abnormality of the nervous system (80-99%), and intracranial cystic lesions (30-79%). Other notable symptoms may include headaches, functional motor deficits, and increased levels of anti-parasite IgE antibodies. While many individuals may remain asymptomatic, the presence of cysts in the brain can lead to serious neurological complications.
To navigate cysticercosis effectively, consider consulting a neurologist who specializes in infectious diseases or neuroinfectious diseases, as they will have the expertise to manage complications associated with neurocysticercosis. Additionally, while there are no specific patient organizations identified, you can access resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Currently, oxfendazole is designated as an orphan drug in development for the treatment of cysticercosis. There are also four active clinical trials exploring various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov and search for cysticercosis: https://clinicaltrials.gov/search?cond=cysticercosis. This research offers hope for improved treatment options in the future.
Actionable guidance for navigating care for cysticercosis
To navigate cysticercosis effectively, consider consulting a neurologist who specializes in infectious diseases or neuroinfectious diseases, as they will have the expertise to manage complications associated with neurocysticercosis. Additionally, while there are no specific patient organizations identified, you can access resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. Participating in clinical trials may also provide access to cutting-edge treatments and contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.